Linus A Volker
Overview
Explore the profile of Linus A Volker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaufeld J, Kuhne L, Schonermarck U, Brasen J, von Kaisenberg C, Beck B, et al.
Kidney Int Rep
. 2024 Oct;
9(10):3081.
PMID: 39430175
[This corrects the article DOI: 10.1016/j.ekir.2024.01.035.].
2.
Kaufeld J, Schonermarck U, Kuhne L, Brasen J, von Kaisenberg C, Beck B, et al.
Kidney Int Rep
. 2024 Jul;
9(7):2307-2308.
PMID: 39081748
No abstract available.
3.
Wendt R, Volker L, Brinkkoetter P
N Engl J Med
. 2024 Jul;
391(4):382-383.
PMID: 39047255
No abstract available.
4.
Kuhne L, Knobl P, Eller K, Thaler J, Sperr W, Gleixner K, et al.
Blood
. 2024 Jun;
144(14):1486-1495.
PMID: 38838300
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency. Caplacizumab, an anti-von Willebrand...
5.
Kaufeld J, Kuhne L, Schonermarck U, Brasen J, von Kaisenberg C, Beck B, et al.
Kidney Int Rep
. 2024 May;
9(4):919-928.
PMID: 38765599
Introduction: In pregnancy-related atypical hemolytic uremic syndrome (p-aHUS), transferring recommendations for treatment decisions from nonpregnant cohorts with thrombotic microangiopathy (TMA) is difficult. Although potential causes of p-aHUS may be unrelated...
6.
Ney S, Gertz R, Pennig L, Nies R, Holtick U, Volker L, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202291
Background: Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical...
7.
Diefenhardt P, Braumann M, Schomig T, Trinsch B, Sierra Gonzalez C, Becker-Gotot J, et al.
J Am Soc Nephrol
. 2023 Jun;
34(8):1366-1380.
PMID: 37367205
Significance Statement: Treatment of acute, crescentic glomerulonephritis (GN) consists of unspecific and potentially toxic immunosuppression. T cells are central in the pathogenesis of GN, and various checkpoint molecules control their...
8.
Volker L, Kaufeld J, Balduin G, Merkel L, Kuhne L, Eichenauer D, et al.
J Thromb Haemost
. 2023 Jan;
21(3):559-572.
PMID: 36696206
Background: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety....
9.
Kuhne L, Kaufeld J, Volker L, Wendt R, Schonermarck U, Hagele H, et al.
J Thromb Haemost
. 2022 Jan;
20(4):951-960.
PMID: 35000278
Background: The anti-von Willebrand factor (VWF) nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of...
10.
Kuhne L, Volker L, Hagmann H, Hagele H, Osterholt T, Eichenauer D, et al.
Br J Haematol
. 2021 Sep;
196(3):e30-e33.
PMID: 34585743
No abstract available.